AIM:NYE-AIM ImmunoTech Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 2.14

Change

-0.02 (-0.93)%

Market Cap

USD 0.10B

Volume

0.44M

Average Target Price

USD 2.00 (-6.54%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.22 (-0.31%)

USD163.29B 24.57 2.73
BHVN Biohaven Pharmaceutical Holdin..

+2.02 (+2.78%)

USD4.70B N/A N/A
RCUS Arcus Biosciences, Inc

+0.76 (+2.34%)

USD2.30B N/A N/A
ADCT ADC Therapeutics SA

+1.61 (+7.08%)

USD1.74B -99,999.99 N/A
MYOV Myovant Sciences Ltd

+0.47 (+2.75%)

USD1.55B N/A N/A
ZYME Zymeworks Inc

+2.12 (+7.59%)

USD1.29B 300.20 N/A
RFL Rafael Holdings, Inc

+0.56 (+1.39%)

USD0.69B N/A N/A
CVM CEL-SCI Corporation

+1.05 (+6.67%)

USD0.65B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
LCTX Lineage Cell Therapeutics, Inc

-0.16 (-6.56%)

USD0.39B 3.63 N/A

ETFs Containing AIM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.55% 46% F 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.55% 46% F 76% C
Trailing 12 Months  
Capital Gain -10.46% 12% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.46% 12% F 4% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 63.35% 84% B 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.35% 84% B 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 111.18% 16% F 4% F
Risk Adjusted Return 56.98% 64% D 71% C-
Market Capitalization 0.10B 32% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.35 67% D+ 98% A+
Price/Book Ratio 1.78 100% A+ 54% F
Price / Cash Flow Ratio -9.96 75% C 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -38.54% 80% B- 10% F
Return on Invested Capital 3.04% 86% B 43% F
Return on Assets -21.77% 68% D+ 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.83 64% D 70% C-
Short Percent 3.41% 67% D+ 54% F
Beta -0.80 96% A 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.